Clinical Scorecard: Epidemiology and Estimated Risk of Invasive Pulmonary Aspergillosis in Mechanically Ventilated COVID-19 Patients: Findings from the Prospective MSG-017 Study Across Seven US Hospitals

At a Glance

Key Highlights

• CAPA incidence was 7% among mechanically ventilated COVID-19 patients; CAPA includes a spectrum from invasive aspergillosis to colonization.
• Single positive mycologic tests (e.g., BAL galactomannan) are insufficient to diagnose IPA; combining multiple test results improves IPA likelihood estimation.
• CAPA is associated with high mortality (71%), but antifungal treatment did not significantly impact mortality; contribution of IPA to death remains unclear.

Guideline-Based Recommendations

Diagnosis

• Use combined host factors, clinical criteria, imaging, and multiple mycologic test results (BAL culture, BAL/serum galactomannan, PCR) to diagnose CAPA.
• Avoid relying on single positive mycologic tests due to risk of false positives in severe COVID-19 patients.
• Apply MSGERC CAPA criteria to differentiate proven, putative, and unlikely IPA.

Management

• Antifungal treatment decisions should consider the likelihood of IPA based on combined diagnostic results.
• Recognize that antifungal treatment has not shown clear mortality benefit in CAPA patients in this study.

Monitoring & Follow-up

• Perform serial mycologic testing including BAL cultures, galactomannan immunoassays, and PCR to monitor Aspergillus presence.
• Follow patients until hospital discharge or death and monitor survival up to 90 days postdischarge.

Risks

• High mortality associated with CAPA (71%) in mechanically ventilated COVID-19 patients.
• False-positive IPA diagnoses may occur with single positive tests leading to potential overtreatment.
• Difficulty distinguishing CAPA from severe COVID-19 lung disease complicates diagnosis and management.

Patient & Prescribing Data

Mechanically ventilated adults with COVID-19 diagnosed with CAPA across seven US hospitals

Antifungal treatment did not significantly reduce mortality in CAPA patients; treatment decisions should be guided by combined diagnostic criteria rather than single test positivity.

Clinical Best Practices

• Use comprehensive diagnostic criteria incorporating host factors, clinical signs, imaging, and multiple mycologic tests to assess CAPA and IPA likelihood.
• Interpret single positive Aspergillus tests with caution due to high false-positive rates in severe COVID-19.
• Consider the full clinical context and test combinations before initiating antifungal therapy.
• Recognize the high mortality risk in CAPA but understand that IPA’s direct contribution to death is uncertain.
• Follow patients longitudinally for outcomes and adjust management based on evolving clinical and diagnostic data.

References

• MSG-017 Study Publication
• European Confederation of Medical Mycology CAPA Definitions
• Mycoses Study Group Education and Research Consortium (MSGERC) CAPA Criteria